Nature Reviews Rheumatology

Article	Citations
Targeting KDM2/7 histone demethylases could protect against OA	499
Synthetic Wnt agonists rapidly rebuild bone in vivo	391
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	327
Annexin A1 could help prevent periprosthetic bone loss	306
Targeted NOD2 sequencing uncovers JIA misdiagnosis	259
Osteoarthritis risk factors differ between sexes	244
aPL target links coagulation and autoimmunity	237
Tapering csDMARDs leads to more RA flares	223
B cell X-chromosome inactivation is faulty in SLE	219
Polygenic risk scores outperform other tests in AS	207
Abatacept for myositis	203
SARS-CoV-2 vaccine safe for young patients	170
Genome-wide mutagenesis reported in systemic sclerosis	167
Stromal cells implicated in RA genetic risk	155
Occupational dust and chemical exposures and the development of autoimmune rheumatic diseases	155
Imaging for prediction of RA development	153
Autoimmune disease increases CVD risk	147
Knee OA progression risk with steroids or HA	141
Are DNA–HLA class II interactions the missing link in SLE?	141
No benefit from adding MTX to ustekinumab	135
Bimekizumab effective across the axSpA spectrum	123
Iron uptake is a therapeutic target in SLE	120
Belimumab an option for Black patients with SLE	109
Inflammatory arthritis affects men’s fertility	101
Response to inflammation differs in gut and joint Treg cells	98

New treatments for amyloidosis	97
Optimizing methotrexate withdrawal during COVID vaccination	93
Cutaneous bacteria promote autoimmunity in mice	91
New OA risk factors and drug targets revealed	91
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	90
Low-dose rituximab can go even lower	90
Helicobacter pylori-induced citrullination linked to RA exacerbation	83
Pre-exposure prophylaxis reduces risk of COVID-19	83
CAR T cells induce remission in a patient with refractory SLE	83
FABP4 exacerbates RA	82
HLA autoimmunity risk alleles influence T cell receptor sequences	80
Risk variant regulates pDC hyperactivation in SLE	78
Targeting articular Mmp13 in OA	77
New guideline for integrative approaches to RA management	76
‘Hyalinization’ for cartilage regeneration	73
Carbamylated NETs promote bone erosion in RA	73
PJP prophylaxis with rituximab	72
BiTE therapy for rheumatic diseases	71
Non-depleting anti-CD19 B cell inhibition	71
Anti-inflammatory TNF receptor 2 signalling unravelled	70
Gut T cells help mediate fracture healing	67
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	66
BiTEing refractory RA	66
Wearable device for RA management?	66
Relapsing polychondritis: clinical updates and new differential diagnoses	65
Mitophagy as a link between ECM stiffness and chondrocyte senescence	65
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	61
Targeting senescence in OA	60
Critical appraisal of serum urate targets in the management of gout	59
Platelets promote cardiovascular complications in Kawasaki disease	58
Kindlin-2 reduces IVD inflammation	57
Nanoparticle-based pazopanib shows promise in OA	56
Benralizumab noninferior to mepolizumab for EGPA	56
ZEB2 promotes formation of age-related B cells	56
Advancing equity in genomic medicine for rheumatology	55
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	54
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	54
Discontinuing methotrexate to enhance vaccine response	53
Proposals for the rheumatological use of JAK inhibitors	53
The new look of classification criteria for systemic vasculitis	53
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	52
Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases	52
Immunological memory in rheumatic inflammation — a roadblock to tolerance induction	50
The emergence of SLE-causing UNC93B1 variants in 2024	48
Shifting the SLE management paradigm: challenges and implications	48
Exploring the latest advances in axial spondyloarthritis management	47
Insights into juvenile myositis via engineered muscle	46
The rise of precision cellular therapies	46
GCA management guidelines — vive la différence?	46
The past 25 years in paediatric rheumatology: insights from monogenic diseases	46

Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	45
Novel autoantigen in idiopathic lung disease	43
Lyme arthritis: linking infection, inflammation and autoimmunity	43
Engineering approaches for RNA-based and cell-based osteoarthritis therapies	42
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	40
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	40
Imaging inflammation with leukocyte-targeted PET tracers	40
Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases	39
Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development	39
Erosive hand osteoarthritis: latest findings and outlook	38
Epidemiology of the idiopathic inflammatory myopathies	38
Emerging concepts of type I interferons in SLE pathogenesis and therapy	37
A role for TGFβ and EBV in MIS-C pathogenesis	36
High risk of autoimmune diseases after COVID-19	35
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis	34
Stem and progenitor cells in the synovial joint as targets for regenerative therapy	34
Post-transcriptional checkpoints in autoimmunity	33
Precision medicine: the precision gap in rheumatic disease	33
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	33
25 years of biologic DMARDs in rheumatology	30
Rheumatic diseases on the rise	30
Biological and clinical roles of IL-18 in inflammatory diseases	29
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce	29
The role of neutrophils in rheumatic disease-associated vascular inflammation	29
Mechanisms and clinical implications of intervertebral disc calcification	29
Which NSAIDs are best for OA treatment?	28
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout	28
Lupus nephritis-related chronic kidney disease	28
Bimekizumab safe and effective for AS and PsA in long-term trials	26
Defining axial involvement in juvenile SpA	25
Ferritin-induced NETs lead to cytokine storm in AOSD	25
Sodium channel Nav1.7 regulates chondrocyte biology and OA progression	24
Anti-TNF dose can be reduced in PsA and axSpA	21
How muscle influences bone health	21
New biomarker panel best yet for prediction of OA progression	21
Use of platelet-rich plasma for knee OA not supported by RCT results	20
PLG nanoparticles target inflammatory monocytes in SSc	20
Freeing PDL1 alleviates autoimmunity	19
Collagen-binding antibody prevents arthritis	19
HLA-B27 linked to progression to axSpA in FDRs	19
Tenascin C promotes pathological bone formation in AS	18
Upadacitinib improves PsA in phase III trial	18
Immune cell profiles stratify AOSD endotypes	17
ETS1 implicated in polarization of tissue-destructive fibroblasts	17
New screening tool developed to aid diagnosis of axial PsA	17
Skin inflammation precedes lesions in cutaneous lupus erythematosus	16
Detachment promotes RA synovial fibroblast survival and invasiveness	15
FOXP3 splice variant is associated with autoimmune disease	15
Pregnancy outcomes in SLE have not improved	15
Defibrotide inhibits NET-mediated thrombosis in APS models	15
Nanohybrid therapy hits multiple arthritis targets	14
Articular cartilage hypoxia is a potential target for OA therapy	14
Mechanism of B cell survival in lupus nephritis	14
Arthritogenic peptide motif identified	13
COVID-19 linked to rise in anti-MDA5 autoimmunity	13
IL-37 has a protective role in IVD degeneration	13
Does psoriasis treatment affect PsA development?	13
BRAVE news: another one bites the dust	13
New drug formulation reduces bone loss	13
Multi-omics reveals distinct MPA subtypes	13
Guselkumab effective through 2 years in PsA trial	13
IKKε promotes catabolic responses in OA	13
Aminoacyl-tRNA synthetases function as alarmins in RA	12
Topical NSAIDs come out top for knee OA	12
Downregulation of invariant chain causes autoreactive T cell expansion	12
IRAK4 inhibitor attenuates inflammation	12
Adropin inhibits fibrosis in SSc	12
JAK inhibitors improve RA pain	12
Ageing stem cells hold the key to age-related bone degeneration	12
SLE risk variant regulates IRF8 expression	11
Evolving concepts in systemic lupus erythematosus damage assessment	11
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	10
The value of comparative efficacy studies in informing rheumatology guidelines	10
Sarcoidosis: can tofacitinib slay the dragon?	10
Understanding synovial cell diversity in post-traumatic OA	10
Ikaros, Aiolos and other moving targets to treat SLE	10
2021 ACR guideline for JIA reflects changes in practice	10
To choose or not? The value of discrete-choice experiments in rheumatology	9
The 2022 ACR vaccination guideline: a call-to-action	9
Keep your Sox on, chondrocytes!	9

Complement therapeutics are coming of age in rheumatology	9
TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out	9
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions	9
Interferon lambda in inflammation and autoimmune rheumatic diseases	8
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	8
Regulation of activated T cell survival in rheumatic autoimmune diseases	8
COVID-19 vaccination in individuals with inflammatory rheumatic diseases	8
Maximizing the success of biosimilar implementation	8